Last updated: September 8, 2026
The citric acid, magnesium oxide and sodium picosulfate combination is an oral bowel-preparation drug used before colonoscopy. Its U.S. commercial history is tied mainly to Ferring Pharmaceuticals’ Prepopik and Clenpiq products. The market has shifted from branded differentiation toward generic price competition, while demand remains linked to colonoscopy volumes, colorectal-cancer screening and gastroenterology procedure capacity.
The combination has limited long-term pricing power because the active ingredients are established, the indication is narrow, and competing bowel-preparation products include low-cost generic polyethylene glycol solutions, sodium sulfate products and tablet-based regimens.
What drugs contain citric acid, magnesium oxide and sodium picosulfate?
The combination is marketed in the United States as a bowel-cleansing preparation. The principal branded products are:
| Product |
Dosage form |
U.S. regulatory status |
Commercial sponsor |
| Prepopik |
Powder for oral solution |
FDA-approved NDA 202535 |
Ferring Pharmaceuticals |
| Clenpiq |
Ready-to-drink oral solution |
FDA-approved NDA 210852 |
Ferring Pharmaceuticals |
| Generic equivalent products |
Powder or oral solution, depending on manufacturer |
FDA-approved ANDA products have entered the market |
Multiple generic manufacturers |
Prepopik was approved by the FDA in 2012 for cleansing the colon before colonoscopy in adults. Clenpiq was approved later as a ready-to-drink formulation using the same active-ingredient combination. The products use sodium picosulfate as a stimulant laxative and magnesium oxide with citric acid to generate magnesium citrate in solution, producing an osmotic cleansing effect. [1,2]
The formulation is supplied with instructions requiring additional clear liquids. This limits the total volume of active preparation compared with traditional four-liter polyethylene glycol regimens, although the patient must still consume substantial supplemental fluid.
How does the formulation work and what clinical advantages does it have?
The combination has three functional components:
| Component |
Role in bowel preparation |
| Sodium picosulfate |
Stimulant laxative that increases intestinal motility |
| Magnesium oxide |
Magnesium source that contributes to osmotic water retention |
| Citric acid |
Reacts with magnesium oxide to form magnesium citrate in solution |
The main commercial advantage is low active-preparation volume. Patients and physicians may prefer a small-volume product when adherence to high-volume polyethylene glycol solutions is difficult. The product is also available in both a powder format and a ready-to-drink liquid format.
Its principal clinical constraints are the risk of dehydration, electrolyte abnormalities and renal complications. The labeling requires caution in patients with renal impairment, congestive heart failure, electrolyte disorders, seizure disorders or medications that affect renal function and fluid balance. [1,2]
The formulation does not eliminate the need for adequate hydration. That distinction matters commercially because the product’s low-volume positioning is based on the volume of the prescription preparation, not the total volume consumed during the regimen.
What is the FDA regulatory status of Prepopik and Clenpiq?
Prepopik and Clenpiq are prescription drugs approved for a procedural indication rather than chronic treatment. Their commercial demand is therefore tied to procedure volumes rather than daily medication use.
| Regulatory event |
Product |
Timing |
| FDA approval |
Prepopik |
2012 |
| FDA approval |
Clenpiq |
2017 |
| Indication |
Both products |
Colon cleansing before colonoscopy in adults |
| Regulatory pathway |
Both products |
505(b)(1) NDA pathway for the branded products |
| Follow-on competition |
Combination products |
ANDA-based generic entry |
The FDA labeling does not establish a broad disease-treatment market. These products are procedural preparations, and prescriptions are generally generated shortly before a scheduled colonoscopy. Refill behavior is therefore limited and recurring revenue depends on the size and frequency of the screening market. [1,2]
When does this combination lose exclusivity?
The active ingredients do not have meaningful composition-of-matter exclusivity. Commercial protection has instead depended on formulation, manufacturing, labeling and product-specific patents, together with regulatory exclusivity.
FDA approval in 2012 places Prepopik well beyond the standard five-year new chemical entity exclusivity period. Clenpiq, approved in 2017, also passed its five-year period in 2022. Any remaining protection would therefore depend primarily on listed patents, pediatric exclusivity, litigation outcomes and the timing of approved generic applications.
The practical exclusivity analysis is:
| Protection category |
Commercial significance |
| New chemical entity exclusivity |
No longer material for the established combination |
| Composition-of-matter patents |
Unlikely to provide durable protection because the ingredients are old |
| Formulation patents |
May delay or narrow generic competition |
| Method-of-use patents |
Limited value for a preparation used primarily before colonoscopy |
| Manufacturing patents |
Can protect production economics but usually do not block all market entry |
| Orange Book patents |
Potential basis for Paragraph IV litigation |
| Labeling exclusivity |
May affect carve-outs but is unlikely to preserve broad brand share |
Exact patent expiration dates must be assessed at the current product-specific Orange Book level because listed patents, pediatric extensions, terminal disclaimers and litigation outcomes can change the effective entry date. The FDA Orange Book is the controlling public source for listed patents and exclusivity attached to approved NDAs. [3]
What patents protect citric acid, magnesium oxide and sodium picosulfate products?
Protection for this class has generally centered on the combined formulation and dosing regimen rather than the individual ingredients.
Formulation patents
Potential claim categories include:
- A powder containing sodium picosulfate, magnesium oxide and citric acid.
- A formulation that produces magnesium citrate after reconstitution.
- Specific ratios of the active ingredients.
- Sachet packaging and moisture-control systems.
- Ready-to-drink liquid formulations.
- Dosing schedules involving two administrations and supplemental clear liquids.
- Stability and manufacturing processes.
These claims can create a period of branded protection, but their strength depends on claim scope. A generic manufacturer may avoid infringement by changing inactive ingredients, packaging, concentration, manufacturing conditions or labeling language while preserving the active ingredients and indication.
Method-of-use patents
Method patents can cover bowel cleansing before colonoscopy, split dosing, administration timing or hydration instructions. Their commercial value is narrower than a product patent because an ANDA applicant may seek a Paragraph IV certification, a section viii statement or a label carve-out for a protected use.
Manufacturing and process protection
Process claims may improve product stability, reconstitution performance or production cost. They are less likely to block a generic product unless the process is necessary to produce the approved dosage form. Manufacturing patents can still affect supply economics, contract-manufacturing negotiations and launch costs.
Which companies are challenging the branded products?
Generic competition is the principal challenge. The combination is chemically simple relative to many specialty drugs, and the brand’s regulatory value rests largely on its established formulation, approved labeling and commercial distribution.
The relevant competitive groups are:
- Generic manufacturers seeking ANDA approval for the same active-ingredient combination.
- Established bowel-preparation companies selling competing formulations.
- Hospital and health-system purchasers using formulary substitution.
- Pharmacy benefit managers and wholesalers negotiating lower-cost alternatives.
Public FDA records should be used to identify each approved ANDA holder and the precise approval status. An ANDA approval does not necessarily mean immediate commercial launch. Launch may be delayed by patent litigation, settlement restrictions, supply constraints, manufacturing validation or commercial decisions by the applicant.
What is the Paragraph IV risk?
Paragraph IV risk is meaningful because the brand products have passed new-drug exclusivity and the active ingredients are widely known. An ANDA applicant can challenge listed patents by alleging that they are invalid, unenforceable or not infringed.
A Paragraph IV filing can produce:
- A 45-day window for the NDA holder to bring infringement litigation.
- A potential 30-month stay of ANDA approval under the Hatch-Waxman framework.
- A negotiated launch date.
- A launch under a patent settlement.
- A commercial launch before patent expiry if the generic applicant prevails or the patents are not enforceable against the proposed product.
The commercial impact depends on whether the challenge targets Prepopik, Clenpiq or both. A powder product may not fully substitute for a ready-to-drink product, but pharmacy and payer pressure can still reduce brand pricing.
No biosimilar pathway applies. This is a small-molecule combination, so competitive entry occurs through ANDAs and potentially 505(b)(2) applications, not through the Public Health Service Act biosimilar pathway.
What competing bowel-preparation drugs affect the market?
The combination competes in a crowded market with products that differ in volume, electrolyte composition, delivery form and price.
| Competitive product class |
Examples |
Competitive advantage |
| Polyethylene glycol solutions |
GoLYTELY, generic PEG-electrolyte solutions |
Low cost and extensive clinical familiarity |
| Sulfate solutions |
Suprep, generic sulfate preparations |
Established low-volume positioning |
| Tablet preparations |
Sutab and other sulfate tablets |
Avoids drinking large volumes of liquid |
| Other low-volume liquids |
Plenvu and related products |
Reduced preparation volume and branded support |
| Sodium picosulfate combinations |
Prepopik, Clenpiq and generics |
Familiar stimulant-osmotic combination |
The main purchasing trade-off is between patient tolerability and acquisition cost. Hospitals and insurers may favor generic PEG or sulfate products, while gastroenterology practices may select branded low-volume or tablet products when adherence and patient experience influence procedure quality.
What is the financial trajectory for the drug?
Standalone revenue for the citric acid, magnesium oxide and sodium picosulfate combination is generally not disclosed by Ferring or public-company manufacturers. Ferring is privately held, and public filings do not provide a reliable product-level revenue series for Prepopik or Clenpiq.
The financial trajectory is therefore best assessed through market structure:
| Period |
Financial characteristic |
| Initial branded launch |
Premium pricing supported by formulation differentiation and physician awareness |
| Expansion with Clenpiq |
Broader delivery-format coverage and potential conversion from powder to liquid |
| Post-exclusivity period |
Increasing payer pressure and generic-entry risk |
| Mature market |
Lower net prices, contracting and volume-based competition |
| Long-term outlook |
Stable procedure-linked demand but limited pricing growth |
Revenue drivers include:
- U.S. colonoscopy screening volumes.
- Medicare and commercial insurance coverage.
- Physician preference for low-volume regimens.
- Generic availability and substitution rates.
- Product shortages affecting competing preparations.
- Hospital formulary decisions.
- Direct-to-patient marketing and gastroenterology sales coverage.
Revenue risks include:
- Generic price erosion.
- Payer-mandated substitution.
- Low-cost PEG alternatives.
- Safety concerns in patients with renal or electrolyte risk.
- Changes in colorectal-cancer screening policy.
- Procedure deferrals caused by healthcare labor shortages or capacity constraints.
A reasonable commercial expectation is declining branded share rather than market disappearance. Colonoscopy demand creates recurring baseline volume, but the combination is unlikely to retain the pricing profile of a protected specialty pharmaceutical after broad generic entry.
How strong is the patent estate?
The patent estate is moderate to weak from a long-term exclusivity perspective.
| Patent-estate factor |
Assessment |
| Active ingredients |
Weak protection because they are established compounds |
| Combination concept |
Potentially protectable but vulnerable to obviousness and design-around arguments |
| Powder formulation |
Moderate value if claims are narrow and technically specific |
| Ready-to-drink formulation |
Moderate differentiation, but substitution risk remains |
| Method of use |
Limited blocking power because the indication is narrow |
| Manufacturing process |
Useful for cost and supply control, less effective as a broad market barrier |
| Regulatory exclusivity |
Expired for Prepopik and Clenpiq’s primary approval periods |
| Generic vulnerability |
High once ANDA applicants obtain approval and patent barriers clear |
The strongest commercial defenses are likely formulation know-how, supply reliability, physician familiarity and payer contracting rather than fundamental patent exclusivity.
What litigation and settlement issues affect generic launch?
A generic launch may be affected by Hatch-Waxman litigation, patent settlements and agreements governing the first commercial entry date. The key questions are whether the generic applicant filed a Paragraph IV certification, whether the NDA holder sued within the statutory period, whether a 30-month stay applied, and whether the case ended in dismissal, settlement or judgment.
For this combination, the most important litigation variables are:
- Whether the challenged patent covers only the branded powder product or also the ready-to-drink formulation.
- Whether a settlement allows an authorized generic.
- Whether the settlement fixes a delayed launch date.
- Whether the generic can launch with a carved-out label.
- Whether several applicants enter simultaneously and accelerate price erosion.
No biosimilar litigation framework applies. Any relevant competition is small-molecule patent litigation or ordinary ANDA approval activity.
What generic launch scenarios exist?
Three scenarios define the commercial outlook:
Early generic entry
An applicant clears patent barriers before all branded formulation patents expire or wins Paragraph IV litigation. Brand pricing falls rapidly, and pharmacy substitution increases.
Staggered entry
One or two generic products launch first, followed by additional manufacturers. The first entrant may preserve some margin, while later entrants produce sharper price declines.
Delayed generic entry
Patent litigation, manufacturing problems or regulatory deficiencies delay approval. The branded products retain a longer period of pricing control, although payer pressure still limits growth.
The most probable long-term scenario for an established bowel-preparation combination is staggered generic entry followed by significant net-price erosion.
What geographic markets matter?
The United States is the most important market for Prepopik and Clenpiq because of the branded products’ FDA approvals and the country’s large colonoscopy market. European and other international markets may use similar active ingredients, but product names, approvals, reimbursement and patent status vary by jurisdiction.
Geographic protection depends on:
- National formulation patents.
- Local regulatory approvals.
- Country-specific generic pathways.
- Reimbursement policy.
- Colonoscopy utilization.
- Local manufacturing and distribution arrangements.
U.S. Orange Book status cannot be used as a proxy for patent protection in Europe, Canada, Japan or emerging markets.
Key Takeaways
- Citric acid, magnesium oxide and sodium picosulfate is a bowel-preparation combination marketed in the United States through Prepopik and Clenpiq.
- Prepopik was FDA-approved in 2012; Clenpiq was approved in 2017.
- The combination has no biosimilar risk because it is a small-molecule product.
- Its commercial protection depends on formulation, method-of-use, manufacturing and listed Orange Book patents rather than new-chemical-entity exclusivity.
- Generic competition is the primary threat to branded revenue.
- The market has recurring demand from colonoscopy procedures but limited long-term pricing power.
- Low-volume and ready-to-drink positioning support differentiation, but generic PEG, sulfate solutions and tablet products create strong substitution pressure.
- Ferring’s product-level revenue is not publicly disclosed, so financial analysis must rely on market structure rather than a verified standalone sales series.
- Patent strength is moderate to weak for long-term blocking purposes because the active ingredients are established and alternative formulations are available.
- The likely financial trajectory is stable procedure-driven volume combined with declining branded share and lower net pricing after generic entry.
FAQs
Is citric acid, magnesium oxide and sodium picosulfate the same as Prepopik?
Yes. Prepopik is a branded formulation containing sodium picosulfate, magnesium oxide and citric acid for bowel cleansing before colonoscopy.
Is Clenpiq a liquid version of Prepopik?
Clenpiq uses the same active-ingredient combination in a ready-to-drink liquid format. It is a separate FDA-approved branded product.
Can generic manufacturers copy Clenpiq?
Generic manufacturers may seek approval for an equivalent product through the ANDA pathway, subject to formulation requirements, patent certifications, labeling restrictions and FDA approval.
Does this drug have biosimilar competition?
No. Biosimilars apply to biologic products. This bowel-preparation combination is regulated as a small-molecule drug, so generic competition is the relevant pathway.
What is the main investment risk for the branded product?
The main risk is generic substitution after formulation and regulatory protections expire. Lower-cost PEG and sulfate products create a second source of pressure even before full generic penetration.
References
-
U.S. Food and Drug Administration. (2012). Prepopik prescribing information. FDA.
-
U.S. Food and Drug Administration. (2017). Clenpiq prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
